Andrew Mendelsohn

Andrew Mendelsohn has extensive work experience in the scientific and research field. Andrew'smost recent role is Chief Scientific Officer at Panorama Research Inc., a position they have held since February 2022. Prior to this, they served as a Senior Scientific Advisor at Corsalex starting in May 2022. In 2019, Mendelsohn co-founded Eumentis Therapeutics Inc., where they held the role of Co-Founder. Andrew also founded and served as the Director of Research at the Regenerative Sciences Institute from 2005 onwards. Mendelsohn co-founded Next Interactions in 2016 and held the position of Co-founder. From 2005 to 2022, they worked as the Director of Molecular Biology at Panorama Research Institute. Mendelsohn co-founded Wntgen LLC in 2013 and served as a Co-Founder until 2019. Prior to these roles, they worked as a Senior Research Fellow at the Molecular Sciences Institute from 1998 to 2004, and as a Research Fellow at Massachusetts General Hospital from 1991 to 1997.

Andrew Mendelsohn obtained a Bachelor of Arts (BA) degree in Biophysics, Natural Science from the University of Pennsylvania, where they studied from 1976 to 1981. Later, they pursued a PhD in Molecular, Cell Biology, and Biochemistry from Brown University, which they completed by 1991.